Real-World Outcomes of SGLT2 Inhibitors in Very Elderly Patients With Heart Failure With Preserved Ejection Fraction
- PMID: 40272336
- DOI: 10.1016/j.jchf.2025.02.011
Real-World Outcomes of SGLT2 Inhibitors in Very Elderly Patients With Heart Failure With Preserved Ejection Fraction
Keywords: SGLT2 inhibitors; comorbidities; heart failure with preserved ejection fraction; very elderly.
Conflict of interest statement
Funding Support and Author Disclosures Dr Antakly-Hanon has received fees from Servier and XO. Dr Piccoli has received fees from Bayer and Pfizer. Dr Hanon has received fees from Novartis, Boehringer-Ingelheim, Lilly, Bayer, BMS, Pfizer, AstraZeneca, Servier, Vifor, Medtronic, Leo pharma, Sanofi Aventis, XO, and GlaxoSmithKline. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.